Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024
Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024
Preclinical data reveal ongoing progress of lead assets and discovery platform as the company prepares to enter the clinic in early 2025
预临床数据显示,随着公司准备在2025年初进入临床阶段,主要资产和发现平台的进展仍在持续
BOSTON, Oct. 10, 2024 /PRNewswire/ -- Sensorium Therapeutics, a biotechnology company developing novel, first-in-class medicines to treat a variety of CNS diseases, announced it presented positive preclinical data on lead programs SENS-01, a novel highly selective fast-acting anxiolytic for the treatment of anxiety disorders, and SENS-03, a novel chemical entity with a differentiated mechanism of action to address focal onset seizures for drug-resistant epilepsy patients, at Neuroscience 2024. The company also shared details on the differentiated capabilities of its Biodynamic Discovery Platform at the conference held this week in Chicago.
2024年10月10日,波士顿 / PRNewswire / -- 生物技术公司 Sensorium Therapeutics 旨在开发新颖且首创的药物来治疗各种中枢神经系统疾病,宣布在2024年的神经科学大会上展示了其领先项目 SENS-01 的积极预临床数据,这是一种用于治疗焦虑症的新型高选择性快速作用的抗焦虑剂;以及 SENS-03,一种具有不同机制的新型化学实体,旨在解决对药物抗性的癫痫患者发作焦虑。该公司还在本周于芝加哥举办的会议上分享了其生物动力学发现平台的差异化能力。
The findings validate Sensorium's de-risked drug development approach, which leverages medicinal chemistry, advanced neuronal screening models, and machine learning to yield novel first-in class CNS medicines inspired by natural compounds and backed by proven human efficacy and safety data.
这些发现验证了Sensorium的降低风险的药物开发方法,利用药物化学、先进的神经元筛选模型和机器学习,生产受天然化合物启发的首创中枢神经系统药物,并支持其已被证明在人类身体上具有有效性和安全性数据。
"These data underscore the potential of our unique drug discovery strategy to develop breakthrough CNS medicines as we prepare to enter the clinic early next year," said Alexandra Glucksmann, PhD, CEO of Sensorium. "They build on the existing value of our first-in-class-programs with potential to address areas of critical unmet need."
Sensorium的首席执行官Alexandra Glucksmann博士表示:"这些数据强调了我们独特的药物发现策略可以开发突破性中枢神经系统药物的潜力,随着我们准备在明年初进入临床阶段。它们基于我们首创项目的现有价值,有望解决关键未被满足领域的需求。"
With a defined mechanism of action and precision pharmacology differentiated from current standard of care, the SENS-01 program comprises a novel molecule—a synthetic derivative of a natural compound with proven human validation as a fast onset anxiolytic— that has demonstrated excellent CNS drug-like properties with a clean safety profile and in vivo efficacy in multiple models. SENS-01 is currently completing IND-enabling studies, with plans to enter the clinic in early 2025.
SENS-01项目具有明确的作用机制和与当前标准护理不同的精密药理学,包括一种新型分子 --一种天然化合物的合成衍生物,经验证在人类身体上作为快速作用型抗焦虑剂,已经在多个模型中展示了优异的中枢神经系统药物样品特性和清洁的安全性记录,目前正快速完成IND启动研究,并计划在2025年初进入临床阶段。
Sensorium is also rapidly advancing its SENS-03 program to address both seizures as well as comorbid anxiety, which is present in 80% drug-resistant patients living with epilepsy. This novel molecule shows efficacy in multiple validated seizure models as well as preclinical anxiety models. With a differentiated mechanism of action from the current standard of care, the SENS-03 program is well positioned to declare a development candidate in early 2025.
Sensorium同时快速推进其SENS-03项目,以解决癫痫发作及合并的焦虑,80%患有癫痫的抗药性患者伴有焦虑。这种新型分子在多种经过验证的癫痫模型以及预临床焦虑模型中表现出疗效。SENS-03项目具有与当前标准护理不同的作用机制,有望在2025年初宣布发展候选药。
Sensorium's Neuroscience 2024 poster presentation details are as follows:
SNTX-AXN, A Novel Fast-Acting Anxiolytic Discovered and Developed from Sensorium's AI-Driven Product Engine
Presented by: Jeffrey Brown, PhD, Chief Scientific Officer
Poster number: PSTR417.21
Key findings:
Sensorium的神经科学2024海报展示详细信息如下:
SNTX-AXN,一种新型快速作用的抗焦虑药物,是由Sensorium的人工智能驱动产品引擎发现和开发的
演讲人:Jeffrey Brown博士,首席科学官
海报编号:PSTR417.21
主要发现:
- Sensorium's development candidate for anxiety disorders is a small molecule synthetic derivative inspired from a natural compound with human validation as a fast-onset anxiolytic and a differentiated pharmacology from standard of care.
- Both in vitro and in vivo data confirm the rapid onset anxiolytic effects reported in humans with the parent natural compound.
- IND-enabling safety studies confirm a clean safety profile, consistent with its unique selectivity to a clinically and commercially validated target.
- Ph1 studies are designed to determine safety, early efficacy readouts, and target engagement using a well-validated clinical biomarker.
- Sensorium针对焦虑症的开发候选药物是一种受自然复合物启发的小分子合成衍生物,经过人类验证,具有快速发作的抗焦虑作用,并且与现有治疗标准的药理学有区别
- 体外和体内数据证实了原始自然复合物中报道的人类快速发作的抗焦虑效果
- IND推进安全性研究证实其独特的选择性对与临床和商业验证的靶点一致,具有良好的安全性概况
- 第一阶段研究旨在通过经过充分验证的临床生物标志物,判断安全性、早期疗效结果和靶点的参与情况。
Sensorium's SENS-AI Platform Identified and Advanced a Novel Therapeutic for Treatment of Epilepsy with Co-Morbid Anxiety
Presented by Jeffrey Brown, PhD, Chief Scientific Officer
Poster number: PSTR056.22
Key findings:
Sensorium的SENS-AI平台确定并提升了一种治疗癫痫伴有焦虑症的新型药物。
由首席科学官Jeffrey Brown博士介绍。
海报号:PSTR056.22
主要发现:
- Sensorium's AI-Driven Product Engine identified a natural compound with human validation of both an anxiolytic and anti-epileptic properties.
- Preclinical data confirm human efficacy data and highlight a mechanism of action differentiated from standard of care.
- Chemical optimization of the natural compound led to novel synthetic derivatives which maintain the efficacy of the natural compound but improved its CNS-drug like properties.
- Sensorium的人工智能产品引擎发现了一种天然化合物,经过人类验证,具有抗焦虑和抗癫痫的特性。
- 临床前数据验证了人类疗效数据,并突出了一种与常规治疗不同的作用机制。
- 对这种天然化合物的化学优化导致了保持天然化合物疗效但改善中枢神经系统药物属性的新型合成衍生物。
A Discovery Platform for Phenotypic Characterization of Natural Products in IPSC-Derived and Primary Neuronal Models
Presented by: Monica Carrasco, PhD, Scientist II, Preclinical Discovery
Alex Lobo, Sr. Research Associate, Preclinical Discovery
Abriel Markowitz, Sr. Research Associate, Preclinical Discovery
Poster number: PSTR375.06
Key findings:
一种用于iPSC衍生和初级神经元模型中天然产物表型特征的发现平台
主讲人: Monica Carrasco博士,科研人员II,临床前发现
Alex Lobo,高级研究助理,临床前发现
Abriel Markowitz,高级研究助理,临床前发现
海报编号: PSTR375.06
主要发现:
- Sensorium has created the most advanced and comprehensive integrated ethnopharmacological knowledge graph to discover molecules with proven human efficacy.
- Novel cellular models leveraging integrated human iPSC-derived and rodent primary neural systems define differentiation and novel pharmacology for compounds.
- Data generated provide a closed-loop system to advance novel drug classifiers and deliver mechanistic insight for novel pipeline compounds currently being advanced.
- Sensorium已创建最先进和全面的整合民族药理知识图,以发现具有经过验证人体功效的分子
- 利用整合的人类iPSC衍生和啮齿类初级神经系统的新型细胞模型,为化合物定义分化和新型药理学
- 生成的数据提供了一个封闭循环系统,用于推进新型药物分类器,并为当前正在推进的新型管道化合物提供机械洞察。
About Sensorium Therapeutics
Sensorium Therapeutics is embracing the complexity of nature and the human brain to bring forth modern medicines to improve the lives of patients with CNS diseases. The company's groundbreaking Biodynamic Discovery Platform combines advanced technologies across chemistry, neuroscience, and machine learning to develop neuropsychiatric drugs inspired by plant-based compounds with evidence of human efficacy. Sensorium's lead asset, SENS-01, is a novel, rapid-acting agent for the treatment of anxiety disorders. For more information, visit .
关于Sensorium Therapeutics
Sensorium Therapeutics正在拥抱自然和人脑的复杂性,推出现代药物来改善患有中枢神经系统疾病的患者的生活。该公司颠覆性的生物动力学发现平台结合了化学、神经科学和机器学习等先进技术,开发受植物化合物启发、具有人类有效性证据的神经精神药物。 Sensorium的主要资产SENS-01是用于治疗焦虑症的新型快速作用剂。获取更多资讯,请访问。
SOURCE Sensorium Therapeutics
资料来源:Sensorium Therapeutics